ReviewFrontiers in neurology2024
Unraveling Alzheimer's disease: insights from single-cell sequencing and spatial transcriptomic.
Review in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multi-omics and high-spatial-resolution omics: deciphering complexity in neurological disorders.GigaScience · 2025Pooled it
- Integrating network medicine and foundation models reveals cell-type-specific regulatory alterations in Alzheimer's disease.NAR genomics and bioinformatics · 2026Article
- Pharmacological modulation of cGAS-STING-NLRP3 signaling by nano-immunomodulators in Alzheimer and Parkinson disease.Inflammopharmacology · 2026Review
- Article
- HDAC11 as a potential therapeutic target for Alzheimer's disease.Drug discovery today · 2026Review
- Conserved Pathways, Divergent Outcomes: A Cross-Species Genomic Perspective on the Cancer-Neurodegeneration Paradox.International journal of molecular sciences · 2026Review
- Circulating microRNA molecular signatures converge with erythroid phenotypes and iron homeostasis in pediatric tic disorders.Frontiers in psychiatry · 2026Article
- Cholinergic regulation of neuroinflammation: linking microglia, immunometabolism, and neuromodulation.Frontiers in immunology · 2026Review
- Advancing the frontiers of ovarian cancer therapy: a comprehensive synthesis of emerging cell death paradigms.Oncology reviews · 2026Review
- The APOE4-estrogen-microglia axis in perimenopausal cognitive changes: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- AβInternational journal of molecular sciences · 2025Article
- UnCOT-AD: Unpaired Cross-Omics Translation Enables Multi-Omics Integration for Alzheimer's Disease Prediction.Briefings in bioinformatics · 2025Article
- Autophagy and Cellular Senescence in Alzheimer's Disease: Key Drivers of Neurodegeneration.CNS neuroscience & therapeutics · 2025Review
- Generative artificial intelligence, integrative bioinformatics, and single-cell analysis reveal Alzheimer's genetic and immune landscape.Molecular therapy. Nucleic acids · 2025Article
- The Neuroimmune Axis in Gastrointestinal Disorders - An Underrecognized Problem.Current gastroenterology reports · 2025Review
- A phage displaying an Aβ-interacting peptide mitigates neurotoxicity and prevents Aβ-driven gene expression changes.Frontiers in molecular neuroscience · 2025Article
- Integrating genetic and immune profiles for personalized immunotherapy in Alzheimer's disease.Frontiers in medicine · 2025Review
- The role of monocytes and macrophages in the progression of Alzheimer's disease.Frontiers in immunology · 2025Review
- Deep contrastive learning framework identifies cell-type-specific drug targets in Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder marked by cognitive decline, primarily affecting memory and executive function. This review highlights recent advancements in single-cell sequencing and spatial transcriptomics, which provide detailed insights into the cellular heterogeneity and neuroimmune mechanisms of AD. The review addresses the need for understanding complex cellular interactions to identify novel therapeutic targets and biomarkers. Single-cell sequencing has revolutionized our understanding by mapping gene expression at the individual cell level, revealing distinct microglial and astrocytic states that contribute to neuroinflammation and neurodegeneration. These technologies have uncovered disease-associated microglial subpopulations and gene expression changes linked to AD risk genes, essential for developing targeted therapies. In conclusion, the integration of single-cell and spatial transcriptomics with other omics data is crucial for a comprehensive understanding of AD, paving the way for personalized medicine. Continued interdisciplinary collaboration will be vital in translating these findings into effective treatments, improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.